Coronary Artery Disease in Patients with HIV Infection

Patel, Amish; Budoff, Matthew J.

doi:10.1007/s40256-015-0105-8

Cited by 15 publications

(14 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, near of 75% patients received two HAART therapy regimens. In HIV patients, non-traditional cardiovascular risk factors are low CD4 count, lipodystrophy syndrome, C hepatitis co-infection, metabolic syndrome, end-stage renal disease and antiretroviral therapy [ 43 ]. The D:A:D study (Data Collection in Adverse Effects of Anti-HIV Drugs) indicated that cumulative exposure to specific protease inhibitor (Lopinavir, Ritonavir and Indinavir) was associated with an increased risk of myocardial infarction (MI) [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial

et al. 2016

View full text Add to dashboard Cite

HIV-seropositive patients show high incidence of coronary heart disease and oxidative stress has been described as relevant key in atherosclerosis development. The aim of this study was to assess the effect of omega 3 fatty acids on different markers of oxidative stress in HIV-seropositive patients. We performed a randomized parallel controlled clinical trial in The Instituto Mexicano del Seguro Social, a public health hospital. 70 HIV-seropositive patients aged 20 to 55 on clinical score A1, A2, B1 or B2 receiving highly active antiretroviral therapy (HAART) were studied. They were randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or placebo for 6 months. At baseline and at the end of the study, anthropometric measurements, lipid profile, glucose and stress oxidative levels [nitric oxide catabolites, lipoperoxides (malondialdehyde plus 4-hydroxialkenals), and glutathione] were evaluated. Principal HAART therapy was EFV/TDF/FTC (55%) and AZT/3TC/EFV (15%) without difference between groups. Treatment with omega 3 fatty acids as compared with placebo decreased triglycerides (-0.32 vs. 0.54 mmol/L; p = 0.04), but oxidative stress markers were not different between groups.Trial RegistrationClinicalTrials.gov NCT02041520

show abstract

Section: Discussionmentioning

confidence: 99%

Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A significant proportion of HIV-infected patients receiving cART develop hyperlipidemia, hyperglycemia, and central obesity [133]. The occurrence of increased carotid intima media thickness, cholesterolemia, triglyceridemia, dyslipidemia, lower homocysteinemia, and increased C-reactive protein levels in HIV-infected children and adults compared with healthy control subjects has been well documented [134]. Clinical studies suggest that HIV-infected patients undergoing cART are at a higher risk for developing cardiovascular disease.…”

Section: Consequences Of Il-18 Dysregulation In Hiv Infectionmentioning

confidence: 99%

Imbalanced production of IL-18 and its antagonist in human diseases, and its implications for HIV-1 infection

et al. 2016

View full text Add to dashboard Cite

“…Cardiovascular disease (CVD) is the leading cause of death worldwide, representing an estimated 30% of all global deaths . This is of particular concern for people living with HIV (PLWH), who have been shown to be at an increased risk for developing atherosclerotic cardiovascular disease (ASCVD) compared with the general population . In high‐income countries, ASCVD is second to cancer as the leading cause of non‐AIDS‐related deaths for PLWH .…”

Section: Introductionmentioning

confidence: 99%

Comparing rates of statin therapy in eligible patients living with HIV versus uninfected patients

2019

View full text Add to dashboard Cite

Objectives Despite an increased risk of atherosclerotic cardiovascular disease (ASCVD) in people living with HIV (PLWH), a gap in statin prescribing practices has been described for statin‐eligble PLWH and uninfected patients. Few data have become available characterizing this gap since the publication of the 2013 American College of Cardiology/American Heart Association lipid guidelines. The objective of this study was to characterize statin prescribing rates for eligible PLWH compared to uninfected adults. Methods This was a retrospective, comparative analysis of patients seen at two clinics in an urban, academic medical system between February 2017 and September 2017. Patients who qualified for one of the statin benefit groups were included: those with a history of clinical ASCVD, low‐density lipoprotein cholesterol ≥ 190 mg/dL, diabetes mellitus, or 10‐year ASCVD risk score ≥ 7.5%. Patients < 21 years old or without a lipid panel within 3 years were excluded. The primary outcome was the percentage of PLWH prescribed a statin compared to uninfected patients. Predictors associated with receiving a statin were analysed using a logistic regression model. Results Nine hundred and eight PLWH and 2239 uninfected patients met the study criteria. A difference in statin prescribing rates was observed between PLWH and uninfected patients (44% versus 56%, respectively; adjusted odds ratio (OR) 0.79; 95% confidence interval (CI) 0.66–0.94). However, only in the 10‐year ASCVD risk group were the rates significantly different (24% for PLWH versus 36% for uninfected patients; adjusted OR 0.68; 95% CI 0.5–0.92). PLWH more often received a medium‐intensity statin and uninfected patients more often received a high‐intensity statin. Conclusions PLWH with ASCVD risk were less likely to be prescribed a statin compared to uninfected patients. Additional analyses are needed to investigate reasons for the statin prescribing gap and appropriateness of lipid agent selection in both study populations.

show abstract

Coronary Artery Disease in Patients with HIV Infection

Cited by 15 publications

References 64 publications

Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial

Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial

Imbalanced production of IL-18 and its antagonist in human diseases, and its implications for HIV-1 infection

Comparing rates of statin therapy in eligible patients living with HIV versus uninfected patients

Contact Info

Product

Resources

About